Homburger advised Santhera on its exclusive North America license for vamorolone to Catalyst
On June 20, 2023, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced the grant of an exclusive North America license for vamorolone to Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) for a total consideration of up to USD 231 m plus royalty payments from product sales. The deal includes a USD 15 m equity investment by Catalyst through the purchase of Santhera treasury shares.
Homburger AG advised Santhera on the Swiss corporate, capital markets and tax law aspects of the transaction. The Homburger team was led by Daniel Häusermann (Corporate / M&A, Capital Markets) and included Stefan Oesterhelt (Tax), Eduard De Zordi and Philipp Klein (both Capital Markets) as well as Jasmin Künzle and Martin Cattaneo (both Corporate M&A, Capital Markets).